CAMELOT FANTASIES

ABcann Goes from RTO to $43 Million in Cash in 3 Months -- CFN Media
9:00 am ET August 3, 2017 (Market Wire) Print
SEATTLE, WA--(Marketwired - Aug 3, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article discussing ABcann Global Corporation's (TSX VENTURE: ABCN) (OTCQB: ABCCF) tremendous progress from its reverse takeover transaction in May to having $43 million in cash now (with a market cap of about $90 million), and where the company is headed over the coming quarters.
High Quality Product
ABcann has spent considerable resources on developing consistent pharmaceutical-grade products that are organically grown without pesticides. This avoids many of the recall issues that other licensed producers have experienced involving the use of banned pesticides. At the same time, the company's $1.5 million, three-year investment in research and development has helped it double industry average yields to cultivate products at a very low cost per gram.
In a recent conversation ABcann CEO Aaron Keay said, "We have spent years mastering our proprietary growing techniques to avoid the use of pesticides. This has led to a repeatable, standardized product the public can trust. Not only that, as our reputation grows in the patients' eyes the word has spread to where we will be expanding our business -- globally. Our dedication to provide a pesticide free, organic, standardized product has resulted in inquiries from industry leaders, competitors, celebrities, and governments."
The high yields of pesticide free, standardized product are especially important when comparing various licensed producers. Production capacity is of course an important metric, and ABcann's proprietary growing methods mean that the company can get much more product out of much less space. Additionally, sizable recalls due to pesticides have impacted several producers' bottom lines, but ABcann removes that possibility by using no pesticides at all.
Rapid Expansion Strategy
ABcann is investing the cash on its balance sheet into an ambitious expansion strategy, which should limit shareholder dilution and accelerate its growth rates. With its proprietary growing technique, the company is in a great position to deploy capital and production knowledge on a massive scale, while competing on both price and quality.
On July 26, the company confirmed that plans to commence construction at its Kimmett facility in the third quarter remain on track and the previously announced plans for a 71,000 sq. ft. Phase I plan have been expanded to 100,000 sq. ft. The company also announced an immediately expansion and construction effort at its production facility in Vanluven to double production capacity and serve its growing patient base on an expedited timeline.
The company believes that its $43 million cash position will be sufficient to complete both the Phase I 100,000 sq. ft. Kimmett facility and the expansion at Vanluven. The Vanluven expansion should begin producing results in Q1'18, while the Kimmett facility should come online by Q4'18. The near-term revenue from these expansion efforts should be sufficient for financing future expansion efforts as recreational legalization goes into effect next year.

ABcann Global Provides Construction and Expansion Update
7:04 am ET July 26, 2017 (Globe Newswire) Print
ABcann Global Corporation (TSX-V:ABCN) (Frankfurt:23Q) (OTCQB:ABCCF) (the "Company") is pleased to provide an update on the Company's construction and expansion timelines for its Vanluven and Kimmett facilities, both located in Napanee, Ontario.
ABcann confirms that plans to commence construction at the Company's Kimmett facility in Q3 2017 remain on track, and the previously announced plans for a 71,000 square foot Phase 1 plan have been expanded to 100,000 square feet. In addition to the Kimmet construction plans, ABcann has initiated immediate expansion and construction at its current production facility at Vanluven to double production capacity and service the Company's growing patient base on an expedited timeline.
ABcann's current cash position is approximately $43 million, which the Company expects will be sufficient to complete both the Phase 1 100,000 square foot construction at Kimmett and the expansion at Vanluven.
"ABcann's strong cash position from its go public transaction, subsequent warrant exercises and recently announced equity financing for $2.25 per share has positioned the Company to aggressively expand our production capacity at both Vanluven and Kimmett," said ABcann CEO and director, Aaron Keay. "The imminent expansion plans and decision to expand our Phase 1 construction plans at Kimmett are in line with ABcann's corporate strategy to take advantage of the current domestic demand for a high quality standardized pesticide free product, in addition to becoming a strong competitor in a number of the emerging markets internationally."
The Kimmett facility will be constructed on a 65 acre property (http://www.abcannglobal.com/Kimmet-Facility.php) that is wholly-owned by the Company and located very close to ABcann's existing Vanluven production facility in Napanee. Our existing acreage provides ABcann the opportunity to continue expansion post Phase 1 construction of up to 1,200,000 square feet of production space. Additional updates and timelines with respect to the Kimmett and Vanluven development plans are as follows:
-- First cultivation from the Kimmett facility is expected in Q4 2018.
-- Kimmett reaching full production capacity is expected in Q1 2019.
-- First cultivation from the expansion areas at Vanluven is expected in Q1 2018.
-- Bird Construction Inc. will act as the General Contractor for both the Kimmett and Vanluven projects (see "About Bird", below).
-- NORR Engineering has been engaged to act as project engineer (see "About NORR", below).
"ABcann has moved methodically through each stage of our growth since first obtaining our license in 2014. Providing a high quality standardized pesticide free product to our patients remains our number one priority as we initiate our largest expansion plans to date," said founder and director, Ken Clement. "With a proprietary growing technique that is repeatable and consistent, we are in a great position to deploy our capital and production knowledge on a massive scale."
Since commencing trading on May 4, 2017, ABcann has received approximately $7.0 million additional dollars through the exercise of warrants.
About Bird:
Bird Construction Inc. ("Bird") is a national general contractor with deep roots in Eastern Canada. Its national reach provides its Eastern Canadian team an unprecedented experience base while still remaining competitive in local markets.
At Bird, the values of Safety, Teamwork, Integrity, People, Professionalism, and Stewardship are the underpinnings of success. With more than 96 years of experience in the construction industry, Bird's unwavering commitment to service delivery, planning and cost-efficient construction strategies has led to many loyal partnerships. As a leading general contractor in Canada, Bird turns ideas into reality through exceptional client service and value creation. Bird's resume includes pre-construction and construction services with a long list of new and repeat clients.
Bird has also become a key design-build and equity member of many public-private partnership projects. With its broad market reach, Bird's clients include leading firms in the commercial, institutional, retail, high-rise residential, industrial, mining, energy, defense construction and civil sectors. Since opening its doors in 1920, Bird has undergone substantial growth, with its employee base nearing 2,000 staff across the country. Bird's success covers most delivery models including Alternative Finance Projects (AFP), design-build, construction management and conventional fixed price contracts. For more information about Bird, see its website at: www.bird.ca.